 |
| |
|
| |
December, 2008 (Issue 76)   | |
|
|
| No truly new drugs have been approved for treatment of asthma since omalizumab (Xolair) in 2003, but some randomized controlled trials of older drugs have been published, and new guidelines have become available. | |
| |
|
| |
| November, 2008 (Issue 75) | top |
|
|
| The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium acnes promote development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation. | |
| |
|
| |
| October, 2008 (Issue 74) | |
|
|
| Osteoporosis is characterized by low bone mass with microarchitectural disruption and skeletal fragility that results in an increased risk of fracture. The diagnosis has traditionally been established by bone densitometry, which is generally reported in terms of standard deviations (SD) from mean values in young adults (T score). The World Health Organization (WHO) has defined normal bone mineral density (BMD) for women as a value within one SD of the young adult mean. Values 2.5 SD (T score -2.5) or more below the mean are defined as osteoporosis. The WHO has developed a computerized model (FRAX) that predicts the 10-year probability of hip fracture based on clinical risk factors and BMD at the femoral neck. | |
| |
|
| |
| September, 2008 (Issue 73) | top |
|
|
| Peptic ulcers caused by treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) are mainly gastric ulcers. The greater the number of office visits and the longer the counseling time, the higher the smoking cessation rates have been. | |
| |
|
| |
| August, 2008 (Issue 72) | |
|
|
| Peptic ulcers caused by treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) are mainly gastric ulcers. Most duodenal and other gastric ulcers are caused by the gram-negative bacillus Helicobacter pylori. Gastroesophageal reflux disease (GERD) is caused by gastric acid reflux into the esophagus. Drugs that suppress gastric acid production are the primary treatment for GERD and peptic ulcers. | |
| |
|
| |
| July, 2008 (Issue 71) | top |
|
|
| The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, diminished insulin secretion and excess hepatic glucose production. Diet, exercise and weight loss are helpful in improving glucose control, but most patients ultimately require drug therapy. | |
| |
|
| |
| June, 2008 (Issue 70) | |
|
|
| Treatment of epilepsy should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures continue and further dosage increases appear inadvisable because of adverse effects, most Medical Letter consultants generally prescribe at least one and sometimes a second alternative drug as monotherapy before considering use of two drugs at the same time. Most antiepileptic drugs initially approved by the FDA only as adjunctive therapy for partial seizures may also be effective for other types of seizures and as monotherapy. Studies suggest that when used for the appropriate seizure type, antiepileptic drugs are roughly equivalent in efficacy. The choice of a drug is usually based on factors such as ease of use, adverse effects and cost. | |
| |
|
| |
|
|
| Arterial and venous thrombosis are major causes of morbidity and mortality. Arterial thrombi consist of platelet aggregates held together by small amounts of fibrin. Antiplatelet drugs are the drugs of choice for prevention and treatment of arterial thrombosis, but anticoagulants are also effective, and their effects can add to those of antiplatelet drugs. Venous thrombi are composed mainly of fibrin and trapped red blood cells, with relatively few platelets. Anticoagulants are the agents of choice for prevention and treatment of venous thromboembolism and for prevention of cardioembolic events in patients with atrial fibrillation. | |
| |
|
| |
| April, 2008 (Issue 68) | |
|
|
| Losing even a small amount of weight and increasing physical activity can prevent some of the complications of obesity, particularly type 2 diabetes. Diet and exercise are the preferred methods for losing weight but are associated with high long-term failure rates. Drugs may help some patients, but all currently available drugs for weight reduction have drawbacks. Gastric surgery can produce marked weight loss in the severely obese, but long-term data on safety are limited. | |
| |
|
| |
| March, 2008 (Issue 67) | top |
|
|
| Some drugs for treatment of migraine attacks are listed in table 2 on page 18. Drugs for prevention of migraine are listed in table 3 on page 20. Treatment of migraine in the emergency room, which may involve use of intravenous drugs, is not included here. | |
| |
|
| |
| February, 2008 (Issue 66) | |
|
|
| Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. They should not be used as a substitute for lifestyle changes; a combination of diet, exercise and lipid-lowering drugs is optimal for prevention of coronary disease. Lipid-regulating drugs must be taken indefinitely; when they are stopped, plasma lipoprotein levels return to pretreatment levels in 2-3 weeks. | |
| |
|
| |
| January, 2008 (Issue 65) | top |
|
|
| The drugs of choice for treatment of some fungal infections are listed in the tables. Some of the indications and dosages recommended here have not been approved by the FDA. Other guidelines are available from the Infectious Diseases Society of America (www.idsociety.org). | |
| |
|
| |
|
|
 FREE
to everyone |
 FREE
to subscribers
Issue is available online to The Medical Letter
subscribers signed up for online privileges. |
 Issue is free to institutional users. |
 $12.00
Non-subscribers may order copies of this
issue of The Medical Letter and receive
by postal mail or electronic download. |
 $10.00
Non-subscribers may purchase online by credit
card on our secure server and download this The
Medical Letter article. |
|
 |
 FREE
to everyone |
 FREE
to subscribers
Issue is available online to Treatment Guidelines
subscribers signed up for online privileges. |
 Issue is free to institutional users. |
 $12.00
Non-subscribers may order copies of this
issue of Treatment Guidelines and receive
by postal mail or electronic download. |
|
|
|
| WANT
TO SUBSCRIBE? |
| Subscribing
online to The Medical Letter or Treatment
Guidelines gives you the following privileges: |
| |
 |
Access to the current issue of The Medical Letter
or Treatment Guidelines (two separate subscriptions)
on the day it is published. |
| |
|
Access
to all articles published by The Medical Letter
since 1988 or to Treatment Guidelines since its
inception (September 2002). |
| |
|
As
a subscriber to The Medical Letter or Treatment
Guidelines, you will also receive your copy of the
current issue by postal mail. |
| |
|
 |
Individual Subscriptions - Individual print and online access, including access to a limited section of the searchable archives. Shared access not allowed. |
|
Individual Librarian Subscriptions - Print and online access for the head librarian only. It allows the librarian to conduct searches and provide data. Shared access not allowed. |
|
Group Site License - Preview Site License. Print and online access for multiple users at multiple locations including access to the entire searchable archives. Please e-mail us for further information regarding The Medical Letter's pricing platform for site licenses. |
|
| |
 |
|
|
| |
| |
